Clinical trials: CNS Germ Cell Tumor, open to volunteers
CNS Malignancies, Medulloblastoma Recurrent
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
This clinical trial is studying a drug called SGT-53 along with radiation and another drug called Nivolumab. It's for children with brain tumors that have come back, gotten worse, or didn't get better with earlier treatments.
- Conditions
- CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma
- Trial name
- JACOB (NCT07017816)
- Testing
- SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Children's National Research Institute
Glioma, Glioneuronal Tumor
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on…
- Conditions
- Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
- Trial name
- NCT05259605
- Testing
- Observational
- Where
- 42 sites in Austria, Belgium and 10 more
- Volunteers
- 1,650 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Intracranial Germ Cell CNS Tumor, Childhood
The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors
Primary endpoint 1. three-year disease-free survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation 2.
- Trial name
- NCT05124951
- Testing
- Whole-ventricle irradiation, Carboplatin/etoposide, Ifosfamide/cisplatin/etoposide
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Beijing Tiantan Hospital